

17/B, Mahal Industrial Estate,
Mahakali Caves Road,
Andheri (East), Mumbai 400 093 India
Tel.: (91-22) 5645 5645
Fax.: (91-22) 5645 5685



PRESS RELEASE

Sun Pharma Board to meet Oct 28: Q2 and H1 results

Oct 18, 2005, Mumbai: The Board of Directors of the speciality pharma company Sun Pharma will meet on the morning of Friday, October 28 to take on record the unaudited financial results for the second quarter and half year ended 30th September, 2005.

Mr. Dilip Shanghvi, Chairman and Managing Director and Mr Sudhir Valia, Wholetime Director will conduct an hour long conference call to discuss the company's performance and take questions. This has been scheduled for the evening of Friday, October 28 at 5 pm.

To participate, please dial the numbers listed below 5 to 10 min before the scheduled start time. The operator will provide instructions on asking questions. As the participation in the call is limited to 70 ports, early registration is suggested.

A replay would also be available two hours after the call at the numbers mentioned below, for three days. The transcript of the call will be posted on www.sunpharma.com.

Details of the numbers to be called:

Mumbai, Toll 5 pm IST, October 28,2005	Primary Access: (+91 22) 2781 2277 Secondary Access: (+91 22) 5591 7977
Playback, Toll Till November 1,2005	Primary Access: (+91 22) 2788 0506 Secondary Access: (+91 22) 5591 7979

About Sun Pharma

Sun Pharma (Reuters : SUN.BO, Bloomberg : SUNP IN, NSE : SUNPHARMA, BSE :524715) is ranked 6th among all Indian pharma companies with a 3.27 % market share (ORG-IMS Stockist Secondary Audit, August 2005). In the Indian market, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, orthopedics, with a rank among the top 3 companies (CMARC March - June 2005). More information about the company can be found at www.sunpharma.com.

Contact

Uday Baldota
Tel : +91 22 5645 5645, Ext 225
E mail: uday.baldota@sunpharma.com

Mira Desai
Tel : +91 22 5645 5645, Ext 184
E mail : miradesai@sunpharma.com,
corpcomm@sunpharma.com